tradingkey.logo
๎™
๎™ผ
tradingkey.logo
๎™

Telomir Pharmaceuticals Inc

TELO
1.210USD
-0.040-3.18%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
35.84M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

Telomir Pharmaceuticals Inc

1.210
-0.040-3.18%

์ž์„ธํ•œ ๋‚ด์šฉ์€ Telomir Pharmaceuticals Inc ํšŒ์‚ฌ

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNAโ€™s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilsonโ€™s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimerโ€™s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ TELO
ํšŒ์‚ฌ ์ด๋ฆ„Telomir Pharmaceuticals Inc
์ƒ์žฅ์ผFeb 09, 2024
CEOAminov (Erez)
์ง์› ์ˆ˜- -
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒFeb 09
์ฃผ์†Œ900 West Platt Street, Suite 200
๋„์‹œTAMPA
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ33606
์ „ํ™”18138642562
์›น์‚ฌ์ดํŠธhttps://telomirpharma.com/
์ข…๋ชฉ ์ฝ”๋“œ TELO
์ƒ์žฅ์ผFeb 09, 2024
CEOAminov (Erez)

Telomir Pharmaceuticals Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.41M
+28.38%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.41M
+28.38%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Feb 25
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Feb 25
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Bay Shore Trust
19.58%
MIRA Pharmaceuticals, Inc.
10.24%
DeJoria (John Paul)
9.44%
McNulty (Brian Patrick)
5.46%
Aminov (Erez)
4.10%
๊ธฐํƒ€
51.18%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Bay Shore Trust
19.58%
MIRA Pharmaceuticals, Inc.
10.24%
DeJoria (John Paul)
9.44%
McNulty (Brian Patrick)
5.46%
Aminov (Erez)
4.10%
๊ธฐํƒ€
51.18%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Corporation
29.82%
Individual Investor
19.11%
Investment Advisor
4.81%
Investment Advisor/Hedge Fund
1.13%
Hedge Fund
0.51%
Venture Capital
0.12%
Research Firm
0.08%
๊ธฐํƒ€
44.42%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Jan 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Jan 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
106
2.38M
6.93%
-810.98K
2025Q3
97
2.75M
8.52%
-985.35K
2025Q2
89
13.66M
45.90%
+660.23K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Bay Shore Trust
6.73M
19.58%
-89.00K
-1.30%
Dec 31, 2024
DeJoria (John Paul)
1.77M
5.16%
+1.77M
--
Sep 09, 2025
McNulty (Brian Patrick)
1.88M
5.46%
-49.00K
-2.54%
Dec 31, 2024
Aminov (Erez)
1.01M
2.94%
+979.88K
+3288.20%
Dec 31, 2024
The Vanguard Group, Inc.
1.10M
3.2%
-16.47K
-1.47%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
287.80K
0.84%
-69.21K
-19.39%
Sep 30, 2025
Geode Capital Management, L.L.C.
196.03K
0.57%
-850.00
-0.43%
Sep 30, 2025
Millennium Management LLC
222.40K
0.65%
-25.30K
-10.21%
Sep 30, 2025
State Street Investment Management (US)
58.60K
0.17%
-3.00K
-4.87%
Sep 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
๋น„์œจ0.01%
iShares Russell 2000 ETF
๋น„์œจ0%
Global X Russell 2000 ETF
๋น„์œจ0%
ProShares UltraPro Russell2000
๋น„์œจ0%
ProShares Hedge Replication ETF
๋น„์œจ0%
Proshares Ultra Russell 2000
๋น„์œจ0%
iShares Russell 2000 Value ETF
๋น„์œจ0%
iShares Russell 2000 Growth ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
KeyAI
๎™